Trial Profile
Daratumumab and Ibrutinib for Symptomatic, Treatment-Naive CLL: A Phase 1b Proof-of-Concept Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 31 Mar 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.
- 22 Aug 2022 Status changed from recruiting to active, no longer recruiting.
- 24 Feb 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2023.